X
-IRRADIATION is an important component of therapy for malignant brain tumorsJ -9"~~ Despite its ability to prolong the survival of patients harboring such tumors, in most cases it remains only a palliative therapy. 2 Among the features that limit its efficacy is the toxicity of the ionizing process to the normal tissue surrounding the neoplasm.7'~ ~.t4-~ 6. 18 Most attempts at enhancing the efficacy of radiation therapy have attempted by pharmacological means to increase tumor radiosensitivity. 4"2~ We have recently established pentobarbital as a radioprotectant for normal brain tissue.~2 This finding has its greatest potential application in the radiotherapy of brain tumors. However, it is critical to the development of this concept that the protective effect of pentobarbital be selective for normal brain parenchyma and not extend to tumor tissue. This investigation was conducted to determine if there is selectivity of this radioprotective effect between normal parenchyma and tumor tissue in an animal model.
Materials and Methods

Animals
Male Fischer 344 rats, each weighing between 150 and 175 gm, were maintained on standard rat chow and water ad libitum. The rats were housed and cared for according to the National Institutes of Health "Guide for the Care and Use of Laboratory Animals, Revised 1985."
Tumor Model
The 9L rat gliosarcoma was grown in tissue culture flasks in a maintenance medium of Dulbecco's minimum essential medium (MEM) supplemented with 10% fetal calf serum, penicillin (10,000 U/ml), streptomycin (100 ug/ml), and 2 mM l-glutamine. At confluence the tumor cells were harvested with 0.4% trypsin and 5 mM ethylenediaminetetra-acetic acid (EDTA), then washed and resuspended in MEM without 1-glutamine at a concentration of 10,000 cells/ul.
Rats were anesthetized with p e n t o b a r b i t a l (45 mg/kg intraperitoneally) and placed in a stereotactic head holder. A m i d l i n e sagittal incision was m a d e and a small c r a n i e c t o m y was p e r f o r m e d 1 m m anterior and 3 m m to the right o f the bregma. The 9L cell suspension (4 ~1) was then injected through the c r a n i e c t o m y with a H a m i l t o n syringe at a depth o f 3.5 m m from the outer table. Bone wax was placed over the craniectomy, the scalp was closed, a n d the a n i m a l was allowed to recover.
X-Irradiation
Five groups o f a n i m a l s were studied, G r o u p 1 served as a t u m o r -b e a r i n g c o n t r o l and received no radiation. G r o u p 2 a n i m a l s were irradiated while a w a k e and restrained in a c o n e -s h a p e d device m a d e o f Lucite with an apical nose o p e n i n g for breathing. A linear accelerator was used as 15 m V source of x-irradiation which was delivered to the whole brain via a lateral port in a single fraction at a dose rate o f 6 G y / m i n a n d a sourceto-target (midsagittal plane) distance of 86 cm. The m o u t h , p h a r y n x , nose, a n d b o d y were shielded with lead. G r o u p 3 received x-irradiation with identical parameters, b u t the r a
d i a t i o n was delivered 15 minutes after i n t r a p e r i t o n e a t a d m i n i s t r a t i o n o f p e n t o b a r b i t a l (60 mg/kg). G r o u p s 4 a n d 5 did not u n d e r g o t u m o r i m p l a n t a t i o n a n d served as irradiated controls. T h e y received 30 G y o f x -i r r a d i a t i o n while awake ( G r o u p 4) or after the a d m i n i s t r a t i o n o f 60 m g / k g o f pentobarbital ( G r o u p 5).
The a n i m a l s f r o m each g r o u p were e x a m i n e d daily and survival t i m e was recorded. T h e survival curves o f G r o u p s 1 t h r o u g h 3 began with t u m o r i m p l a n t a t i o n , with that d a y being designated as Day 0. F o r calculation of survival time, the survival curves of G r o u p s 4 and 5 were offset such that the day o f their x-irradiation was designated as D a y 8, j u s t as in G r o u p s 1 through 3. Survival t i m e was calculated for G r o u p s 4 a n d 5 begin-ning with the day o f death o f the last t u m o r -b e a t i n g animal. The data were analyzed with Student's t-test for unpaired data.
Autopsies were p e r f o r m e d on all t u m o r -i m p l a n t e d animals to d o c u m e n t the success of this procedure.
Results
The results are s u m m a r i z e d in Table 1 
a t i n g animal had grossly visible t u m o r at the i m p l a n t a t i o n site.
Discussion
The d a t a from the investigation reported here confirms, as others have shown, that radiation therapy prolongs the survival of animals implanted with the 9L tumor. 3'~24 The addition of pentobarbital sedation before administration of the same dose of x-irradiation further enhances survival time. This demonstrates that the tumor was not protected by the pentobarbital. If the pentobarbital had protected the tumor tissue from radiation injury, the tumor would have been expected to grow more quickly than it did in the group of tumorbearing animals that were irradiated while awake. This would have led to a more rapid death in the pentobarbital-treated group than in the awake group. This was not the case. Rather, the pentobarbital-treated group had a longer mean survival period. Although there was improvement in the survival period, all animals eventually died from tumor; thus no cure occurred with the radiation parameters used in this study.
The 30-Gy radiation control groups (Groups 4 and 5) are also reported as part of an accompanying series of experiments which investigated the mechanism and dose-response characteristics of protection against radiation-induced brain injury by pentobarbital. ~3 We chose 30 Gy as the radiation dose for the investigation reported here because it was the highest dose at which 100% survival occurred with the addition of pentobarbital in our radiation dose-survival response experiments. '3 Because deaths occurred in nontumor-bearing animals which were irradiated while awake, the decrement in survival of the group of tumor-bearing animals that were irradiated while awake (Group 2) is due to combined radiation-and tumor-induced injury. At higher doses of radiation in the dose-survival response study, deaths occurred even with the addition of pentobarbital. ~3 Thus, at higher doses of radiation, deaths from radiation toxicity would have been happening simultaneously with tumor-induced deaths; the inability to separate these causes of death in the tumorbearing group treated with pentobarbital (Group 3) would have made data interpretation difficult. Thus, limitation of the radiation dose to a level that affected tumor growth (Group 2) but at which no radiation-induced deaths occurred in control pentobarbitaltreated animals (Group 5) meant that the enhanced survival time with radiation during pentobarbital treatment could be considered a result of protection of brain, and not tumor, from radiation injury.
To examine the influence of pentobarbital on radiation-induced tumor response required a tumor-bearing model in which tumor response could be measured. We chose to deliver radiation 8 days following tumor implantation because, at 7 days after implantation, tumor is visible to the naked eye and treatment of a small tumor was more likely to demonstrate any possible benefits. Alternative hypotheses to explain the improved survival of animals pretreated with pentobarbital are that this manipulation increased the radiosensitivity of the tumor or that pentobarbital as used here had some direct tumor-inhibiting effect. Prior work addressing the alteration of radiosensitivity of tumors or normal tissue by pentobarbital has been performed with many different experimental models and has produced conflicting conclusions. Investigators utilizing rodent models with subcutaneously implanted tumors have reported that pentobarbital is capable of increasing, decreasing, or having no effect on tumor radiosensitivity and have demonstrated no direct effect of pentobarbital on these tumors. 6'1v, '9 In 1957, Alvord and Brace ~ described alteration of radiation injury to cerebellar granule cells in a guinea pig; however, no specific work on the alteration of radiosensitivity using intracranial tumor models has been reported since. As all tumor-beating animals in this study eventually died of their tumor at the dose of radiation used, whether treated with pentobarbital or not, the alteration of radiosensitivity and tumor growth which might be significant in terms of final outcome requires investigation of increasing doses of radiation.
This investigation addresses the issue of preferential radioprotection of normal brain over tumor based on implanted tumor model. The prospect of application of cerebral radioprotection by pentobarbital is most easily projected in reference to tumor treatment. It may offer a mechanism by which survival time as well as quality of survival can be enhanced. Although the data presented here are of potential relevance, we caution that 1) there is a significant species difference, 2) the tumor is sarcomatous in nature, and 3) the most important dose-limiting toxicity with radiation therapy of brain-tumor patients is late delayed toxicity. This study investigated the differential protection of tumor and normal brain against acute and early delayed radiation damage. Direct extrapolation to humans with malignant brain tumors is not appropriate. Further investigation of this phenomenon is warranted prior to unqualified recommendations about its potential utility in the clinic.
